List view / Grid view
1 August 2016 | By Takeda Pharmaceutical Company Ltd and Seattle Genetics, Inc.
Takeda and Seattle Genetics announce that the ALCANZA trial evaluating ADCETRIS for cutaneous T-cell lymphoma demonstrated significant improvement...
1 August 2016 | By RedHill Biopharma Ltd.
RHB-104 for relapsing-remitting multiple sclerosis show positive safety and efficacy signals after the 24-week treatment period ...
1 August 2016 | By GlobalData
Growth will be driven by the uptake of novel oral anticoagulants, which represent important advances over warfarin, a cheap and established anticoagulant, says new report...
1 August 2016 | By Sanofi / Regeneron Pharmaceuticals, Inc.
Sanofi and Regeneron Pharmaceuticals, Inc. have announced that the European Medicines Agency has accepted for review the Marketing Authorisation Application for sarilumab, an investigational human monoclonal antibody directed against the IL-6 receptor that is intended for the treatment of adult patients with moderately to severely active rheumatoid arthritis...
29 July 2016 | By Mandy Parrett, Editorial Assistant
Shire Plc has announced today that the United States Food and Drug Administration (FDA) has granted Fast Track designation for SHP626 (volixibat) for an investigational treatment of adults with nonalcoholic steatohepatitis (NASH) with liver fibrosis.
Lab M Ltd, a Neogen company, introduces its Pinnacle™ MMGA (ISO), Mineral Modified Glutamate Agar, pre-poured media plate. The new plate is formulation compliant to ISO 16649-1 and performance compliant to ISO 11133 for the recovery of stressed and injured E. coli in food, water and feed samples.
28 July 2016 | By ObsEva
ObsEva initiates Phase 1 clinical program of OBE022, a first-in-class orally active Prostaglandin F2alpha antagonist, for the treatment of preterm labor...
28 July 2016 | By Pluristem Therapeutics Inc.
Pluristem Therapeutics Inc. has today announced its intentions to conduct a Phase III trial assessing its PLX-PAD cells in recovery following surgery for femoral neck fracture, which is the most common form of hip fracture...
28 July 2016 | By Sanofi
U.S. Food and Drug Administration (FDA) have approved Sanofi's Adlyxin TM (lixisenatide), a once-daily mealtime GLP-1 receptor agonist injection indicated as an adjunct to diet and exercise for the treatment of adults with type 2 diabetes...
27 July 2016 | By Niamh Louise Marriott, Digital Content Producer
Laurent Pharmaceuticals has received a Therapeutics Development Award of $3 million from US-based Cystic Fibrosis Foundation Therapeutics...
27 July 2016 | By Niamh Louise Marriott, Digital Content Producer
US FDA has approved Viekira XR (dasabuvir, ombitasvir, paritaprevir and ritonavir) for the treatment of chronic genotype 1 (GT1) hepatitis C...
26 July 2016 | By Niamh Louise Marriott, Digital Content Producer
Trubberzi is an oral medication taken to relieve the main symptoms of irritable bowel syndrome with diarrhoea (IBS-D) in adults...
26 July 2016 | By Niamh Louise Marriott, Digital Content Producer
Axol Bioscience have signed a collaboration agreement to improve, standardise and more accurately predict the risk of human clinical pro-arrhythmias...
25 July 2016 | By Niamh Louise Marriott, Digital Content Producer
Ipsen announced that CHMP & EMA have provided a positive opinion for Cabometyx for the treatment of advanced renal cell carcinoma (RCC) in adults...
25 July 2016 | By Niamh Louise Marriott, Digital Content Producer
Morphochem announced today that the U.S. FDA has designated Morphochem’s intravenous antibacterial product as a Qualified Infectious Disease Product...
